The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017.


Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
04 2019
Historique:
received: 04 05 2018
revised: 22 10 2018
accepted: 11 11 2018
pubmed: 8 1 2019
medline: 16 7 2020
entrez: 8 1 2019
Statut: ppublish

Résumé

Osteoporosis and osteopenia are increasingly prevalent conditions among older adults. Not only do the fractures associated with poor bone health have significant health consequences for the individual, but also their economic impact is placing increasing financial burden on governments and society. This study aimed to determine the direct economic cost of osteoporosis, osteopenia, and fractures among Australians aged 50 years and older in 2017. This study uses previous Australian data on the incidence and prevalence of osteoporosis and osteopenia together with recent Australian data on health service utilization after fracture to provide an estimate of the economic burden of osteoporosis. A bottom-up costing approach was used to determine the average direct health care and non-health care total costs of a fracture, as well as the average community health service costs of managing individuals with osteoporosis or osteopenia. The total direct cost of osteoporosis in Australia in 2017 was estimated to be $3.44 billion (AUD 2017, USD 2.77 billion). Treatment of fractures accounted for 68% of total direct costs, and non-fracture management of osteoporosis accounted for 32%. Hip fractures accounted for the highest proportion (43%) of the total direct cost of fractures, although fractures at "other" sites accounted for 38.5%. Fractures among individuals aged 70 years and older accounted for 74% of the direct costs (55% and 19% in women and men, respectively). Fracture costs in those with osteopenia accounted for 50% of direct fracture treatment costs. This up-to-date cost analysis estimated that costs in 2017 were three times higher than in 2007. These estimates will aid clinicians, policy makers, researchers, and health care organizations to acknowledge the economic importance of reducing osteoporosis-related fractures and associated costs. This provides a strong public health case to promote bone health that will assist in reducing future fracture-related costs. © 2018 American Society for Bone and Mineral Research.

Identifiants

pubmed: 30615801
doi: 10.1002/jbmr.3640
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

616-625

Subventions

Organisme : National Health and Medical Research Foundation Council
ID : 68251
Pays : International
Organisme : Merck Australia Pty Ltd
Pays : International

Informations de copyright

© 2018 American Society for Bone and Mineral Research.

Auteurs

Gemma Tatangelo (G)

School of Psychology, Deakin University, Burwood, Australia.

Jennifer Watts (J)

Deakin Health Economics, Centre for Population Health Research, Deakin University, Geelong, Australia.

Karen Lim (K)

Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

Catherine Connaughton (C)

Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

Julie Abimanyi-Ochom (J)

Deakin Health Economics, Centre for Population Health Research, Deakin University, Geelong, Australia.

Fredrik Borgström (F)

LIME/MMC, Karolinska Institutet, Solna, Sweden.

Geoff C Nicholson (GC)

Department of Medicine, The University of Melbourne and Western Health, Sunshine Hospital, Melbourne, Australia.
Rural Clinical School, The University of Queensland, Toowoomba, Australia.

Catherine Shore-Lorenti (C)

Department of Medicine, The University of Melbourne and Western Health, Sunshine Hospital, Melbourne, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.

Amanda L Stuart (AL)

School of Medicine, Deakin University, Geelong, Australia.

Sandra Iuliano-Burns (S)

Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Australia.

Ego Seeman (E)

Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Australia.

Richard Prince (R)

School of Medicine and Dentistry, University of Western Australia, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, Australia.

Lyn March (L)

Institute of Bone and Joint Research, University of Sydney-Royal North Shore Hospital, Sydney, Australia.

Marita Cross (M)

Institute of Bone and Joint Research, University of Sydney-Royal North Shore Hospital, Sydney, Australia.

Tania Winzenberg (T)

Menzies Research Institute Tasmania, University of Tasmania, Tasmania, Australia.

Laura L Laslett (LL)

Menzies Research Institute Tasmania, University of Tasmania, Tasmania, Australia.

Gustavo Duque (G)

Department of Medicine, The University of Melbourne and Western Health, Sunshine Hospital, Melbourne, Australia.
Ageing Bone Research Program, Sydney Medical School, Nepean Hospital, University of Sydney, Sydney, Australia.

Peter R Ebeling (PR)

Department of Medicine, The University of Melbourne and Western Health, Sunshine Hospital, Melbourne, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.

Kerrie M Sanders (KM)

Department of Medicine, The University of Melbourne and Western Health, Sunshine Hospital, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH